NLC Health Ventures (Amsterdam, The Netherlands), in partnership with Verily, the precision health technology daughter company of Alphabet/Google, will launch Exolvo Biosciences, a pioneering biotech company providing the next-generation solution for biologic drug delivery as oral administration.

Valneva announces Health Canada approval of the world’s first chikungunya vaccine, IXCHIQ®.

Tubulis doses first patient in phase 1/2a trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary linker technology with better biophysical properties that demonstrated effective and durable responses in a range of preclinical models.  

The BIOSECURE Act of the United States could affect more than 120 US biopharmaceutical drugs partnered with Chinese companies ‘of concern’, as named in the bill. Of these, approximately half are in clinical trials (phases I to III) and a third are in early preclinical and discovery stages, according to GlobalData, the analytics company.

A new Chief Business Officer strengthens the management team of Macomics Ltd (UK). Simon Drew took over the newly created position in June.

French dairy giant Danone, engineering materials group Michelin, US start-up DMC Biotechnologies and Crédit Agricole Centre France have joined forces to create the Biotech Open Platform as  precision fermentation centre.

German researchers have tracked down the causes for central nervous system side effects of cancer immunotherapies and blocked them in small animal models.

In the rapidly evolving healthcare landscape, the concept of 4P Medicine—Prevention, Prediction, Precision, and Participation—marks a transformative shift towards personalized healthcare. This approach, refined over the last 15 years, aims to revolutionize how we understand, prevent, and treat diseases by focusing on each patient’s unique needs. The recent whitepaper by Worldwide Clinical Trials highlights the profound impact of 4P Medicine on clinical development and patient care.

A print magazine focussing on start-ups in the life sciences! Like a catalyst, it aims to promote young companies in the life sciences with the right impulses.

Evotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS).